1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real‐world assessment of practice efficiency with the introduction of subcutaneous rituximab
    Meeting Abstract

    Matasar, M. J.; Qiu, A.; Shapouri, S.; Drill, E. N.; Schade, J.; Ravelo, A.; Ni, A.; To, T. M.; Dawson, K. L.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Multi‐center phase II study of oral azacitidine (CC‐486) plus CHOP as initial treatment for peripheral T‐cell lymphoma
    Meeting Abstract

    Ruan, J.; Leonard, J. P.; Coleman, M.; Rutherford, S.; Van Besien, K.; Rodriguez, A.; Benderoff, L.; Mehta‐Shah, N.; Moskowitz, A.; Sokol, L.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Dose finding study to assess safety, PK and efficacy of fimepinostat (CUDC‐907) with venetoclax or rituximab plus bendamustine in patients with relapsed/refractory lymphoma
    Meeting Abstract

    Younes, A.; Batlevi, C. L.; Cohen, J. B.; Kelly, K.; Landsburg, D. J.; Patel, K.; Phillips, T.; Smith, S.; Westin, J.; Ma, A. W.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Allogeneic hematopoietic cell transplantation impacts on immune evasive mechanisms in relapsed/refractory diffuse large B‐cell lymphoma – A single center experience
    Meeting Abstract

    Sauter, C. S.; Lin, R. J.; Ho, C.; Devlin, S. M.; Maloy, M. A.; Perales, M.; Dahi, P. B.; Schoder, H.; Jakubowski, A. A.; Barker, J. N.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and clinical activity of atezolizumab in combination with tazemetostat in relapsed or refractory diffuse large B-cell lymphoma: Primary analysis of a phase 1B study
    Meeting Abstract

    Palomba, M. L.; Cartron, G.; Popplewell, L.; Ribrag, V.; Westin, J.; Chitra, S.; Huw, L.; Newberry, K.; Raval, A.; Xu, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Exceptional response of refractory ATLL with MDM4 amplification to novel stapled peptide dual MDM4/2 inhibitor
    Meeting Abstract

    Janakiram, M.; Ye, H. B.; Carjaval, L.; Villaorduna, A.; Ramesh, K.; Shah, U.; Kornblum, N.; Fehn, K.; Braunschweig, I.; Ueda, K.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Updated analysis of genetic sequencing of North American ATLL
    Meeting Abstract

    Janakiram, M.; Villaorduna, A.; Sica, R.; Kornblum, N.; Braunschweig, I.; Chung, E.; Shah, U. A.; Wang, Y.; Verma, A. K.; Ye, H. B.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Grade 3A follicular lymphoma can be effectively controlled with very low dose radiation therapy
    Meeting Abstract

    Imber, B. S.; Chau, K.; Goldberg, E.; Joffe, E.; Yahalom, J.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B‐cell lymphomas
    Meeting Abstract

    Jagadeesh, D.; Horwitz, S.; Bartlett, N. L.; Advani, R.; Jacobsen, E.; Duvic, M.; Gautman, A.; Rao, S.; Onsum, M.; Fanale, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Managing cytokine release syndrome (CRS) and neurotoxicity with step‐up dosing of mosunetuzumab in relapsed/refractory (R/R) B‐cell non‐Hodgkin lymphoma (NHL)
    Meeting Abstract

    Sehn, L. H.; Assouline, S.; Bartlett, N. L.; Bosch, F.; Diefenbach, C. M.; Flinn, I.; Hong, J. Y.; Kim, W. S.; Matasar, M.; Nastoupil, L.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save